CSIMarket
 
Shockwave Medical Inc   (SWAV)
Other Ticker:  
 
 
Price: $334.7500 $-0.08 -0.024%
Day's High: $334.9 Week Perf: 0.19 %
Day's Low: $ 334.71 30 Day Perf: 1.38 %
Volume (M): 4,715 52 Wk High: $ 334.90
Volume (M$): $ 1,578,212 52 Wk Avg: $254.15
Open: $334.85 52 Wk Low: $157.00



 Market Capitalization (Millions $) 12,879
 Shares Outstanding (Millions) 38
 Employees 253
 Revenues (TTM) (Millions $) 787
 Net Income (TTM) (Millions $) 164
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 32

Shockwave Medical Inc
Shockwave Medical Inc. is a growing medical technology company based in Santa Clara, California, that aims to transform the way cardiovascular diseases are treated. The company specializes in developing products that employ a unique technology known as intravascular lithotripsy (IVL) to treat coronary and vascular calcified lesions.

Founded in 2009 by Dr. John Adams, the company has been successful in raising capital from well-known venture capitalists such as Norwest Venture Partners, Venrock, and Fidelity Management & Research Company, and has been listed on the NASDAQ under the ticker "SWAV" since March 2019. The company's mission is to develop innovative tools to disintegrate calcified arterial plaque, improving patient outcomes and quality of life.

Shockwave's technology, IVL, is a non-invasive, photoacoustic intravascular ultrasound-guided technique that utilizes sound waves to break down calcifications within arteries. The device uses an ultrasound probe to visualize the calcifications and deliver high-frequency sound waves to break them up into small particles that can be naturally eliminated by the body. This process differs from conventional treatment methods such as rotational atherectomy or laser atherectomy, which use a rotating blade or a laser to grind or vaporize plaque.

Shockwave's flagship device is the Shockwave Intravascular Lithotripsy System, which has received regulatory approval in the USA, Europe, and Japan. The device is approved for use in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD) in the lower legs. The Shockwave System has several benefits over conventional approaches to treating calcified lesions, including the ability to treat longer, more complex lesions with less injury to the artery walls and an improved safety profile due to a lower risk of perforation.

The company has amassed positive clinical trial data, including the DISRUPT PAD study, which demonstrated that the Shockwave System improved blood flow in more than 80% of patients with calcified PAD and that the benefits persisted at 12-month follow-up. Additionally, the DISRUPT CAD study suggested IVL was safe and effective in patients with calcified coronary lesions, with a low rate of procedural complications.

In recent years, the company has expanded its product pipeline, including the recent launch of the Shockwave S4 catheter, a next-generation version of the Shockwave Lithoplasty System. The company's sales have been increasing rapidly, and it continues to expand its geographical presence worldwide, with an increasing number of clinicians recognizing the benefits of the Shockwave System.

Overall, Shockwave Medical has established itself as a foremost leader in the field of cardiovascular disease treatment, with an innovative technology and a product portfolio that are poised to have significant impact on the treatment of patients with cardiovascular calcifications.


   Company Address: 5403 Betsy Ross Drive Santa Clara 95054 CA
   Company Phone Number: 279-4262   Stock Exchange / Ticker: NASDAQ SWAV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BSX        4.17% 
EW   -0.36%    
MDT   -1.78%    
ABT   -0.9%    
• View Complete Report
   



Shockwave Medical Inc

Shockwave Medical Inc. Achieves Impressive Double-Digit Growth in Medical Equipment & Supplies Industry

In the first quarter of 2024, Shockwave Medical Inc reported exceptionally impressive earnings that showcased the company's strong performance and growth in the Medical Equipment & Supplies industry. The company's revenue saw a remarkable increase of 35.72% to $218.60 million, while the profit per share rose by 39.81% to $1.44 per share compared to the previous year.
These outstanding financial results not only surpassed the industry average, which saw an overall 6.01% growth, but also exceeded the company's own revenue of $203.60 million and profit per share of $1.15 in the previous reporting season. This remarkable year-on-year growth signifies the company's ability to outperform its competitors and indicates a positive trend for the future.

Clinical Study

Coronary Sinus Reducer and Shockwave Reducer Combo Show Promising Results in Treating Refractory Angina

Published Mon, Apr 8 2024 8:03 PM UTC

Sophisticated The Coronary Sinus Reducer (CSR) and Shockwave Reducer have been garnering attention for their positive outcomes in treating refractory angina. This chronic condition, characterized by severe chest pain and reduced quality of life, affects millions of people worldwide. Recent findings from the REDUCER-I Trial further support the efficacy of these innovative tec...

Shockwave Medical Inc

Investors Show Confidence in Shockwave Medical's Financial Performance and Future Growth

Shockwave Medical Inc. has experienced a significant gain in its stock price over the past five trading days, with a 12.01% increase. This rise in stock price has contributed to the company's year-to-date gains of 32.87%. Additionally, Shockwave Medical Inc.'s stock is currently trading on the NASDAQ at 13.1% above its 52-week average. These positive developments indicate that investors have confidence in the company and its future prospects.
In its recent financial report for the three months and full year ended December 31, 2023, Shockwave Medical Inc. highlighted several key achievements. The company's earnings per share (EPS) soared to $1.15, a significant increase compared to the previous year. This improvement can be attributed to the company's growing revenue, which saw a remarkable growth rate of 41.361% to reach $203.60 million.

Shockwave Medical Inc

EPS Remains Steady Amidst Strong Growth for Shockwave Medical Inc in Q3 2023

Shockwave Medical Inc (NASDAQ: SWAV) has reported strong financial results for the third quarter of 2023, with earnings per share remaining steady at $0.92 compared to the previous year, indicating stability and consistent performance. Profits also showed significant growth, increasing by 21.05% to $0.76 per share from the preceding reporting season.
The company's revenue experienced a remarkable jump of 41.253% to $185.51 million from $131.33 million in the same period last year. Sequentially, the revenue advanced by 3.248% from $179.67 million. It is worth noting that Shockwave Medical Inc has outperformed its industry peers, as the rest of the Medical Equipment & Supplies industry reported revenue growth of only 3.80% during the same period.

Shockwave Medical Inc

Shockwave Medical Inc Shocks the Industry with Record-Breaking Q2 2023 Performance



Shockwave Medical Inc, a leading Medical Equipment & Supplies company, has recently released its latest fiscal second-quarter financial results. The company has showcased substantial growth in income per share, outperforming its industry counterparts on the top-line front. Additionally, revenue has witnessed a significant increase, driving positive earnings growth. Amidst these positives, the company's focus on improving sales has led to a slight decline in net margin. Furthermore, there has been an evident buildup in inventories and accounts receivable, indicating rising demand.
Financial Results:
1. Income per Share Growth:
For the fiscal second quarter of 2023, Shockwave Medical Inc's income per share has grown by 11.76%, reaching $0.76 per share. This growth can be compared to $0.68 per share reported a year prior. However, there has been a slight decline of -26.21% from the preceding financial reporting period where the income per share was $1.03.
2. Revenue Growth:
Shockwave Medical Inc's revenue has seen a substantial jump of 48.802% to $179.67 million in the fiscal second quarter of 2023 compared to $120.75 million in the same period a year prior. The sequential growth in revenue also showcases an 11.552% increase from $161.07 million.







Shockwave Medical Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com